SAGE Therapeutics (SAGE) Given “Buy” Rating at Stifel Nicolaus

SAGE Therapeutics (NASDAQ:SAGE)‘s stock had its “buy” rating reiterated by research analysts at Stifel Nicolaus in a research report issued to clients and investors on Friday, December 8th. They currently have a $198.00 price target on the biopharmaceutical company’s stock. Stifel Nicolaus’ price target suggests a potential upside of 18.80% from the stock’s current price.

Several other research analysts also recently issued reports on the stock. SunTrust Banks raised their price objective on shares of SAGE Therapeutics to $178.00 and gave the stock a “positive” rating in a research report on Friday, December 8th. Raymond James Financial restated a “buy” rating and issued a $206.00 target price on shares of SAGE Therapeutics in a research note on Thursday, December 7th. Canaccord Genuity set a $191.00 target price on shares of SAGE Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 7th. Needham & Company LLC raised their target price on shares of SAGE Therapeutics from $100.00 to $193.00 and gave the stock a “buy” rating in a research note on Thursday, December 7th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and issued a $198.00 target price on shares of SAGE Therapeutics in a research note on Friday, December 8th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $171.21.

Shares of SAGE Therapeutics (NASDAQ:SAGE) traded up $1.95 on Friday, hitting $166.66. 441,562 shares of the stock were exchanged, compared to its average volume of 1,080,000. The firm has a market cap of $6,840.00, a price-to-earnings ratio of -24.26 and a beta of 3.03. SAGE Therapeutics has a fifty-two week low of $44.55 and a fifty-two week high of $173.36.

SAGE Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.98) by $0.01. The business’s revenue was up .0% on a year-over-year basis. analysts anticipate that SAGE Therapeutics will post -7.42 earnings per share for the current fiscal year.

In other SAGE Therapeutics news, insider Albert Robichaud sold 60,000 shares of the business’s stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the completion of the sale, the insider now directly owns 152,759 shares in the company, valued at $24,354,367.37. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jeffrey M. Jonas sold 210,247 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $157.45, for a total transaction of $33,103,390.15. Following the sale, the chief executive officer now owns 211,473 shares of the company’s stock, valued at $33,296,423.85. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of SAGE. Russell Investments Group Ltd. lifted its position in shares of SAGE Therapeutics by 20.5% during the second quarter. Russell Investments Group Ltd. now owns 23,722 shares of the biopharmaceutical company’s stock worth $1,889,000 after purchasing an additional 4,043 shares in the last quarter. TD Asset Management Inc. raised its holdings in SAGE Therapeutics by 4.9% in the second quarter. TD Asset Management Inc. now owns 76,630 shares of the biopharmaceutical company’s stock valued at $6,103,000 after acquiring an additional 3,600 shares in the last quarter. Pioneer Investment Management Inc. raised its holdings in SAGE Therapeutics by 126.9% in the second quarter. Pioneer Investment Management Inc. now owns 158,418 shares of the biopharmaceutical company’s stock valued at $12,616,000 after acquiring an additional 88,585 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in SAGE Therapeutics in the second quarter valued at $175,000. Finally, Schwab Charles Investment Management Inc. raised its holdings in SAGE Therapeutics by 5.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 138,179 shares of the biopharmaceutical company’s stock valued at $11,005,000 after acquiring an additional 6,739 shares in the last quarter. 95.33% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “SAGE Therapeutics (SAGE) Given “Buy” Rating at Stifel Nicolaus” was first published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.truebluetribune.com/2018/01/03/stifel-nicolaus-reaffirms-buy-rating-for-sage-therapeutics-sage.html.

SAGE Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply